Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | GRK2 | P25098 | 2/20 | 0.41 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780967 | 0.89 | ROCK2 (0.44) | ROCK2ROCK1AKT1GRK2PRKACA | |
| SCHEMBL779756 | 0.89 | ROCK2 (0.48) | ROCK2ROCK1AKT1PRKACAPRKACG | |
| SCHEMBL781886 | 0.87 | ROCK2 (0.55) | ROCK2ROCK1AKT1GRK2GRK5 | |
| SCHEMBL781562 | 0.82 | ROCK2 (0.49) | ROCK2ROCK1AKT1GRK2GRK1 | |
| SCHEMBL18008931 | 0.80 | LATS1 (0.44) | ROCK2ROCK1RPS6KB1AKT2 | |
| SCHEMBL21812217 | 0.80 | LATS1 (0.44) | ROCK2ROCK1RPS6KB1AKT2 | |
| SCHEMBL782046 | 0.78 | ROCK2 (0.52) | ROCK2ROCK1AKT1GRK2GRK1 | |
| SCHEMBL780434 | 0.78 | RPS6KB1 (0.41) | ROCK2ROCK1GRK2GRK1GRK5 | |
| SCHEMBL800865 | 0.78 | ROCK2 (0.48) | ROCK2ROCK1GRK2GRK1GRK5 | |
| SCHEMBL780619 | 0.77 | LMNA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | claimed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | claimed |
| EP-3259265-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | Sentinel Oncology Limited (GB) | 2017-12-27 | — | — | EP | claimed |
| WO-2016131776-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2016-08-25 | — | — | WO | claimed |
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| EP-3259265-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | Sentinel Oncology Limited (GB) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016131776-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2016-08-25 | — | — | WO | disclosed |
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | RPS6KA1, RPS6KA3, MTOR | ROCK2 374/4885ROCK1 175/4885AKT1 58/4885 |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | ROCK2 733/4885ROCK1 699/4885AKT1 95/4885 |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | RPS6KA1, RPS6KA3, MTOR | ROCK2 374/4885ROCK1 175/4885AKT1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.